• About
    • Login
    View Item 
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Safety and Effectiveness: The FDA’s Approach to Risk in Prescription Medication

    Philip Gentry, Anne Elissa
    : https://etd.library.vanderbilt.edu/etd-04042016-131002
    http://hdl.handle.net/1803/12003
    : 2016-04-11

    Abstract

    The Food and Drug Administration (FDA) regulates the risks associated with pharmaceutical products; however, some drug uses are not directly regulated, and appropriate usage is left to the physician’s discretion. These risks can often be ambiguous or uncertain. In this dissertation, I study how consumers respond to ambiguity in pharmaceutical risk. I also examine two areas where risk is either not directly regulated or is perceived to be insufficiently regulated—I study whether patients, physicians, and third-party payers are sensitive to these risks or whether further regulation would be preferable. This dissertation begins by using an incentivized experiment to empirically estimate participants’ reactions to ambiguity in risks that a drug is unsafe or ineffective in the presence of framing effects. The experiment finds that attitudes toward ambiguity are sensitive to risk type and framing effects. The dissertation then concentrates on two areas where risk is not directly regulated: The second chapter studies narrow therapeutic index drugs, drugs for which the generic approval process has been suspected to be inadequate in ensuring therapeutic equivalence. It finds evidence of a price penalty for the extra risk associated with NTI drugs. The third chapter studies off-label uses—the prescription of a drug for an unapproved use—and examines whether inappropriate off-label uses are relinquished even in the absence of direct FDA regulation. It finds evidence that relinquishment of off-label uses can be spurred by False Claims Act suits. The dissertation provides insight into areas in which parties seem sensitive to risk absent regulation and those in which further regulation may be necessary.
    Show full item record

    Files in this item

    Icon
    Name:
    Gentry.pdf
    Size:
    6.844Mb
    Format:
    PDF
    View/Open

    This item appears in the following collection(s):

    • Electronic Theses and Dissertations

    Connect with Vanderbilt Libraries

    Your Vanderbilt

    • Alumni
    • Current Students
    • Faculty & Staff
    • International Students
    • Media
    • Parents & Family
    • Prospective Students
    • Researchers
    • Sports Fans
    • Visitors & Neighbors

    Support the Jean and Alexander Heard Libraries

    Support the Library...Give Now

    Gifts to the Libraries support the learning and research needs of the entire Vanderbilt community. Learn more about giving to the Libraries.

    Become a Friend of the Libraries

    Quick Links

    • Hours
    • About
    • Employment
    • Staff Directory
    • Accessibility Services
    • Contact
    • Vanderbilt Home
    • Privacy Policy